newsfilter
← Latest News
Business Wire·

Quanterix Releases Financial Results for the Second Quarter of 2026

QTRX
  • Quanterix reported $32.9 million in revenue for the second quarter ended June 30, 2026, representing a 34% increase from the prior year.
  • The company ended the quarter with $96.9 million in cash, cash equivalents, marketable securities, & restricted cash.
  • GAAP gross margin was 38.5% while adjusted non-GAAP gross margin was 47.9% for the quarter.
  • Adjusted EBITDA (non-GAAP) loss was $10.0 million, an improvement from the $13.7 million loss in the prior year period.
  • The company recorded a $26.9 million goodwill impairment related to the Akoya acquisition, which does not impact operations or liquidity.
  • Quanterix revised its 2026 revenue outlook downward to $142-$148 million from a previous expectation of $169-$174 million.
  • The company extended its projected cash-flow break-even date from 2026 to 2027.
  • Adjusted cash usage for the quarter was $4.0 million, a decrease of $10.8 million compared to the first quarter of 2026.
  • Senior leadership appointments included Jim Gute as Chief Commercial Officer, Geoff Albrecht as SVP & GM of Diagnostics, Anthony Catalano as COO, & Jason Faessler as CFO.
  • Anthem Blue Cross & Blue Shield announced coverage for Quanterix's Lucent AD® Complete testing effective July 1, 2026.
  • Quanterix was selected as a Co-Investigator in the PD-BUILD program to develop biomarker tools for Parkinson's disease research.
  • New product launches included Simoa® Ultra-Sensitive Immunoassay NPTX2, a Spatial Molecular Barcoding kit, & Spatial Spectral DAPI 2.0.
  • The company completed its ERP system integration, finalizing the Akoya acquisition program & realizing $85 million in annualized savings.
  • Non-GAAP gross margins for 2026 are now forecasted in the range of 48-50%.
  • Quanterix expects to end 2026 with approximately $80 million in cash & no debt.